Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: Long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial

RMD Open

Volumn 3, Issue 2, 2017, Pages

  Sigaux, Johanna ^a   Bailly, Florian ^a   Hajage, David ^a,b   Mariette, Xavier ^c,d   Morel, Jacques ^e   Gandjbakhch, Frédérique ^a,f   Foltz, Violaine ^a,f   Gossec, Laure ^a,f   Tubach, Florence ^a   Fautrel, Bruno ^a,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIV MONTPELLIER   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Anti TNF; Rheumatoid Arthritis; Treatment

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

EID: 85034602094     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000474     Document Type: Article

References (27)

1. Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
2. den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2010;49:1801-3.
3. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infiximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18:460-4.
4. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
5. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infiximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
6. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infiximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
7. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Modern Rheumatology 2014;24:17-25.
8. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
9. den Broeder AA, van Herwaarden N, van der Maas A, et al. Dose reduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299.
10. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389.
11. Verhoef LM, Tweehuysen L, Hulscher ME, et al. bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search. Rheumatol Ther 2017;4:1-24.
12. Bouman CA, van Herwaarden N, van den Hoogen FHJ, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study-a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis 2017.
13. Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol 2015;33:63-8.
14. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59-67.
15. Prevoo MLL, Van'T Hof MA, Kuper HH, et al. Modifed disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Furst DE, Shaikh SA, Greenwald M, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Care Res 2015;67:151-60.
18. van Vollenhoven R F, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.
19. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, effcacy and safety (phase Iiib ALLOW study). Ann Rheum Dis 2012;71:38-44.
20. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infiximab. Arthritis Rheum 2006;54:3782-9.
21. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfiximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
22. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infiximab and anti-adalimumab antibodies in relation to response to adalimumab in infiximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
24. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
25. Bingham CO, Mendelsohn AM, Kim L, et al. Maintenance of clinical and radiographic beneft with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 effcacy and safety results of the open-label long-term extension of a phase III, double-blind, randomized, placebo-controlled trial. Arthritis Care Res 2015;67:1627-36.
26. Sigaux J, Hamze M, Daien C, et al. Immunogenicity of tocilizumab in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:39-45.
27. Lillegraven S, Prince FH, Shadick NA, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681-6.